



ARTICLE

Translational Therapeutics

Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: a summary of preclinical studies

Yuki Kita¹, Akihiro Hamada¹, Ryoichi Saito¹, Yuki Teramoto², Ryusuke Tanaka³, Keishi Takano⁴, Kenji Nakayama^{1,5}, Kaoru Murakami¹, Keiyu Matsumoto¹, Shusuke Akamatsu¹, Toshinari Yamasaki¹, Takahiro Inoue¹, Yasuhiko Tabata³, Yasushi Okuno⁶, Osamu Ogawa¹ and Takashi Kobayashi¹

BACKGROUND: Since the standard gemcitabine and cisplatin (GC) chemotherapy for advanced bladder cancer yields limited therapeutic effect due to chemoresistance, it is a clinical challenge to enhance sensitivity to GC.

METHODS: We performed high-throughput screening by using a library of known chemicals and repositionable drugs. A total of 2098 compounds were administered alone or with GC to human bladder cancer cells, and chemicals that enhanced GC effects were screened.

RESULTS: Disulfiram (DSF), an anti-alcoholism drug, was identified as a candidate showing synergistic effects with cisplatin but not with gemcitabine in multiple cell lines. Co-administration of DSF with GC affected cellular localisation of a cisplatin efflux transporter ATP7A, increased DNA–platinum adducts and promoted apoptosis. Micellar DSF nanoparticles (DSF-NP) that stabilised DSF in vivo, enhanced the inhibitory effect of cisplatin in patient-derived and cell-based xenograft models without severe adverse effects. A drug susceptibility evaluation system by using cancer tissue-originated spheroid culture showed promise in identifying cases who would benefit from DSF with cisplatin.

CONCLUSIONS: The present study highlighted the advantage of drug repurposing to enhance the efficacy of anticancer chemotherapy. Repurposing of DSF to a chemotherapy sensitizer may provide additional efficacy with less expense by using an available drug with a well-characterised safety profile.

British Journal of Cancer <https://doi.org/10.1038/s41416-019-0609-0>

BACKGROUND

Bladder cancer is the ninth most common cancer worldwide, with 430,000 new cases and 165,000 deaths worldwide each year.¹ Muscle-invasive bladder cancer (staging classification T2 and above) is associated with high rates of lymph node involvement and distant metastasis. Metastatic bladder cancer cannot be completely resected by surgery. Thus, muscle-invasive bladder cancer and metastatic bladder cancer have a very poor prognosis, with 5-year survival rates of 50 and 20%, respectively.²

Cytotoxic chemotherapy has been the standard treatment for advanced bladder cancer. However, treatment outcomes in unresectable urothelial carcinoma (UC) did not improve for more than 30 years until very recently, with the introduction of immune checkpoint inhibitors. Despite the current trends for the increasing use of immune checkpoint inhibitors, the response rates are far from sufficient.³ Thus, platinum-based cytotoxic chemotherapy is still the treatment of choice for advanced bladder cancer in many contexts. However, the initial response rate for gemcitabine (GEM) and cisplatin (CDDP), one of the standard systemic chemotherapies for advanced bladder cancer, is ~50–70% due

to intrinsic resistance.⁴ Even in responders, many tumours develop acquired resistance and regrow after a short time. Thus, the development of a novel method to enhance the efficacy of cytotoxic chemotherapy for advanced bladder cancer without compromising tolerability is critical.

In recent years, the concept of drug repurposing, in which existing approved drugs are developed and adapted as a therapeutic drug for other diseases, has attracted attention.⁵ The established safety of the candidate compounds provides several advantages compared with the development of new therapeutic compounds. The time and cost required to advance a candidate treatment into clinical trials can also be substantially reduced because in vitro and in vivo screening, chemical optimisation, toxicology studies, bulk manufacturing and formulation development have, in many cases, already been completed and can therefore be bypassed.

To develop a novel therapeutic strategy that enhances the efficiency of GC chemotherapy for bladder cancer, here we applied a high-throughput screening by using a library of known chemicals and repositionable drugs. We demonstrate a novel

¹Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan; ²Department of Diagnostic Pathology, Kyoto University Graduate School of Medicine, Kyoto, Japan; ³Laboratory of Biomaterials, Department of Regeneration Science and Engineering, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan; ⁴Department of Environmental and Health Sciences, Hokkaido Institute of Public Health, Sapporo, Japan; ⁵Shimadzu Techno-research, Kyoto, Japan and ⁶Department of Clinical System Onco-Informatics, Kyoto University Graduate School of Medicine, Kyoto, Japan
Correspondence: Osamu Ogawa (osamuogawa1219@gmail.com)

Received: 2 May 2019 Revised: 24 September 2019 Accepted: 2 October 2019

Published online: 01 November 2019

strategy with potential clinical application, from in vitro screening, through proof-of-principle experiments, to preclinical evaluation in mice and development of an efficacy prediction system by using cancer tissue-originated spheroid (CTOS) culture of human bladder cancer.

METHODS

Cell culture

Human bladder cancer cell lines UMUC3, J82, T24, HT1197 and HT1376 were purchased from American Type Culture Collection (Manassas, VA) within 6 months from the initiation of this study. Cells were cultured in RPMI-1640 supplemented with 10% foetal bovine serum, 25 mM HEPES, 100 U/mL penicillin and 100 U/mL streptomycin in a 37 °C humidified environment containing 5% CO₂.

Compound library

Screening compounds were provided from the Medical Research Support Center, Graduate School of Medicine, Kyoto University. The library consists of 2098 known drugs and small-molecule compounds with a history of use in human clinical trials, collected from Prestwick Chemical library, Calbiochem® inhibitors and Selleckchem® inhibitor library. The compounds were solubilised in dimethyl sulfoxide (DMSO) to a final concentration of 10 mM, formatted in 96-well microtiter plates and stored at –80 °C.

Screening methodology

All 2098 compounds were tested in UMUC3 and J82 cells in duplicate. Cells were seeded in 96-well tissue culture plates. The following day, each of the compounds was added to a well at a final concentration of 10 µM with or without GEM and CDDP (fixed ratio of 1:100) (Fig. 1a). The fixed ratio of cisplatin to gemcitabine was determined according to a previous study⁶ that adopted the ratio based on the respective IC₅₀s for gemcitabine and cisplatin. We confirmed this by ourselves for the two cell lines we used in the initial screening: 1:87.7 for UMUC3 and 1:63.9 for J82. Then we determined IC₂₀ values of concentrations of gemcitabine and cisplatin cocktail (1:100) for each cell line. Each plate had a column of untreated wells for normalisation between plates. After 72 h, water-soluble tetrazolium salt-8 (WST-8) was added, plates were read at 450 nm by a plate reader and statistical computation was done. The optical density (OD) 450 for a compound-treated well was normalised by dividing with the average of the untreated wells on the same plate. Hit compounds were selected with [GC + compound/GC < 0.5] and [compound alone/vehicle > 0.7] in both cell lines.

Western blot

Cell lysis, sodium dodecyl sulfate–polyacrylamide gel electrophoresis and Western blot analysis was performed as described previously.⁷

In vitro cytotoxicity assays and dose-effect analysis

Cells plated in 96-well plates were treated with 10 µM DSF and various concentrations of GEM and CDDP with a fixed ratio of 1:100 for 72 h and assayed by WST-8 assay. Combination index values for the treatments were determined by using CalcuSyn software (Biosoft, Ferguson, MO, USA). Combination index values of <1, =1 and >1 indicated synergism, additive and antagonism between the drugs, respectively.

Apoptosis assay

Apoptosis was determined by using the FITC-conjugated Annexin-V/PI assay kit (Roche, Basel, Switzerland) and flow cytometry following the manufacturer's instructions. Annexin-V-positive cells were classified as early apoptotic cells, and Annexin V and PI double-stained cells were classified as late apoptotic or necrotic cells.

Quantitative analysis of intracellular reactive oxygen species (ROS) and platinum (Pt)–DNA adducts

Production of ROS was analysed by flow cytometry, as described previously.⁸ For intracellular Pt–DNA adducts, UMUC3 cells were treated with 10 µM DSF and GC (CDDP, 100 µM; GEM, 10 nM) for 1 h, and DNA was extracted by using the QIAampDNA MiniKit (Qiagen, Hilden, Germany). Extracted DNA was resuspended in 0.5 mL of nitric acid and digested with 10 mL of nitric acid and 0.1 mL of perchloric acid for 3 h at 180 °C. The samples were fixed in 3 mL of 0.1 M nitric acid solution and analysed by using quadrupole-induced coupled plasma mass spectrometry (ICP-MS: iCAP Qc, Thermo Fisher Scientific, Bremen, Germany). The Pt reading was normalised to the DNA concentration. For measuring whole cellular Pt, cell lysates were pooled after addition of an equal volume of nitric acid and were digested by using the same method of the Pt–DNA-adduct analysis. The Pt reading in the cells was normalised to the protein concentration.

Immunofluorescence and immunohistochemistry

For immunofluorescence staining, UMUC3 cells were seeded on an eight-well chamber slide, pre-treated with or without 10 µM DSF and GC (CDDP, 100 µM; GEM, 10 nM) for 1 h and then subjected to immunofluorescence staining by using the primary antibody to ATP7A (Santa Cruz, sc-376467) and the secondary ALEXA Fluor™ 488-conjugated antibody (Abcam, ab150105). Slides were mounted in VECTASHIELD with DAPI (Vector Laboratories, Burlingame, CA, USA). Confocal microscopy images were taken by a Leica TCS SP2, and seven randomly selected fields were quantitatively analysed on Image J.

For immunohistochemical evaluation of ATP7A expression, we used surgical specimens from 31 patients with bladder UC (Supplementary Table 1). All patients had clinically muscle-invasive disease (≥cT2) except for one patient (cT1). All patients received transurethral resection (TUR) of untreated tumour, neoadjuvant CDDP-based systemic chemotherapy (GC in 18, MVAC in 11 and others in 2) and radical cystectomy (RC) at Kyoto University Hospital. After approval by the Institutional Review Board at Kyoto University Graduate School of Medicine (#G0052-17), TUR and RC specimens were subjected to IHC. A trained pathologist (Y. Te.) and two authors (Y.K. and T.K.) independently scored ATP7A staining intensity into four grades (G0–3), and discrepant cases were resolved by discussion with all observers.

Preparation and characterisation of DSF nanoparticles (DSF-NP)

DSF-loaded nanoparticles were prepared by using an emulsion-solvent evaporation method. Poly (L-lactic acid) (weight-average molecular weight = 5000) (100 mg) and DSF (100 mg) were dissolved in 2 mL of dichloromethane and mixed with 20 mL of 2 wt% polyvinyl alcohol (weight-average molecular weight = 44,000, degree of saponification = 85.5%) aqueous solution. This mixture was homogenised for 30 s by a vortex mixer and sonicated for 10 min to produce an oil-in-water emulsion. The organic phase was evaporated for 12 h at room temperature. The solution was centrifuged at 10,700g for 30 min, and the supernatant was centrifuged again at 96,600g for 30 min to obtain DSF-incorporated nanoparticles (DSF-NP). DSF-NP was washed twice with water and freeze-dried. The apparent size of NPs was determined by dynamic light scattering by using a ZETASIZER NANO ZS90 (Malvern Panalytical, Almelo, The Netherlands). The amount of DSF entrapped in nanoparticles was determined by using HPLC by UV detection at 250 nm (SHIMADZU LC-20). After dissolution in dichloromethane and evaporation of dichloromethane at room temperature, DSF was dissolved in pure ethanol. The mobile phase was a mixture of acetonitrile:water (80:20), and the flow rate was set at 1 ml/min. Separation was achieved by using a Cosmosil 5C₁₈-MS-2 column (150 mm × 4.6 mm).




Fig. 1 Combinatorial high-throughput screen identified DSF as a synergistic sensitizer of CDDP. **a** Chemical screening strategy. UMUC3 and J82 cells were treated with GC at IC₂₀ concentrations alone or in combination with 2,098 compounds from the chemical library. After 72 h, cell viability was determined by using WST-8 assay. **b, c** Each compound is expanded scatter according to the relative cell viability of treatment with compound alone to the control (water) and relative cell viability of treatment with GC plus compound to GC alone (**b**; UMUC3, **c**; J82). Hit compounds are shown in the dashed squares (compound alone/control ≥ 0.7 and GC + compound/GC ≤ 0.5). Red dots indicate DSF and yellow dots indicate vehicle. **d** Venn diagram showing eight compounds that sensitised both UMUC3 and J82 cells to GC in the initial screening. Further validation narrowed the compounds into the strongest sensitizer, DSF, an FDA-approved drug for alcoholism. **e** Enhancement of GC cytotoxicity by DSF in bladder cancer cells. Five bladder cancer cell lines were treated with 10 μM DSF, and varied concentrations of GEM (indicated on the x axis) and CDDP were fixed at a ratio of 1:100 for 72 h and evaluated by WST-8 assay. **f** Combination index for combined treatments of Gem plus DSF, CDDP plus DSF and GC plus DSF was determined by using CalcuSyn software. A combination index < 1 (dotted line) denotes synergy. DSF shows synergism with CDDP but not with Gem in all cell lines

Cell-derived xenograft (CDX) model
BALB/cAJcl-nu/nu mice (7-weeks old) were purchased from CLEA Japan Inc. All animal experiments were conducted in accordance with the guidelines of the Laboratory Protocol of Animal Care and

Use Committee, Kyoto University. To evaluate tolerability of the combination regimen, three mice were treated with CDDP (4 mg/kg i.v.) and DSF-NP (3 mg/body i.v.). Body weights were measured once a week, and serum creatinine levels were measured 1 week

Table 1. Clinicopathological characteristics and outcomes of 15 urothelial carcinoma patients subject to CTOS assay

Patient #	Age, sex	Pathology, disease stage	Establishment of CTOS (>20 spheres)	Sensitivity
#01	83, M	HG, >pT2	No	–
#02	82, M	LG (G1), pTa	Yes	No
#03	75, F	HG with squamous dif., pTa	No	–
#04	69, M	HG (G2 > 3), pT1	No	–
#05	76, M	HG (G2), pTa	Yes	CDDP + DSF
#06	76, M	HG (G2), pTa	No	–
#07	81, M	HG (G3), >pT2	No	–
#08	81, F	HG (G3), >pT1	No	–
#09	47, M	HG (G3), pT2	Yes	CDDP + DSF
#10	49, M	HG (G3), >pT1	No	–
#11	92, M	HG (G2 > G3), pT1	No	–
#12	74, M	HG (G3), pT1	Yes	CDDP alone, CDDP + DSF
#13	87, M	HG, pT1	No	–
#14	69, M	HG (G2), pTa	Yes	CDDP + DSF
#15	80, M	HG (G2), pT1	Yes	CDDP + DSF

HG high grade, LG low grade, CDDP cisplatin, DSF disulfiram

after administration. A UMUC3 subcutaneous xenograft model was prepared by inoculating the right flank of mice with 3.0×10^6 UMUC3 cells with Matrigel®. One week later, the mice were randomly divided into four groups ($n = 7$), receiving saline, CDDP (4 mg/kg body weight), DSF-NP (150 mg/kg body) or CDDP + DSF-NP via tail-vein injection. A T24 subcutaneous xenograft model was prepared by inoculating the right flank of mice with 2.0×10^6 T24 cells with Matrigel®. Two weeks later, the mice were randomly divided into four groups ($n = 3$) receiving saline, CDDP (3 mg/kg body weight), DSF-NP (150 mg/kg body) or CDDP + DSF-NP via the tail vein. The tumour volume was calculated by the following formula: $V = (L \times W^2) \times 0.5$, where L is the largest and W is the orthogonal diameters of the tumour.

Patient-derived xenograft (PDX) models

We established two lines of PDX from human invasive bladder cancer specimens according to previously reported methods.^{9,10} The developed xenograft was divided into 12 equal parts and passaged to 12 CB-17/lcr-crj SCID mice (Charles River, Yokohama, Japan) (7-week old). After 2 weeks, the mice were randomly divided into four groups ($n = 3$) receiving saline, CDDP (4 mg/kg body weight), DSF-NP (150 mg/kg body) or CDDP + DSF-NP via the tail vein. Tumour volume was measured as described above. In both CDX and PDX models, inoculation of cell lines and tumour pieces, and tail injection of drugs, were performed under inhalation anaesthesia with isoflurane. The dose of cisplatin was based on previous reports,^{6,11} and the dose of DSF-NP was determined as 40 nmol/body weight (g), equivalent to the concentration that showed an effect in vitro. Tumour-bearing mice were killed by using carbon dioxide gas at the end of experiment, or when the tumour size exceeded 2 cm in diameter.

Pt-DNA-adduct staining and TdT-dependent dUTP-biotin nick end labelling (TUNEL) assay

For Pt-DNA-adduct staining, tumour sections were deparaffinised, antigen recovered, blocked with 1% BSA/PBS for 1 h at room temperature, incubated with a 1:500 dilution of anti-CDDP modified DNA, Rat-Mono (CP9/19) (Novus, NBP2-50165) at 4 °C overnight and then incubated with goat anti-Rat IgG (H + L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 546 (1:1000, Invitrogen, A11081). Apoptosis was detected by TUNEL assay by using an apoptosis detection kit (Promega, Madison, WI, USA) following the manufacturer's instructions.

Chemosensitivity assay with cancer tissue-originated spheroid (CTOS)

We established CTOSs from PDX and TUR specimens (Table 1), as described.¹² CTOSs were injected into Matrigel® droplets and cultured in conditioned medium with vehicle, DSF (10 µM), CDDP (10–1000 µM) or DSF + CDDP in 96-well plates. Photographs of each CTOS were taken at days 1 and 6, and the CTOS volume was calculated as follows: $\text{volume} = (L \times W^2) \times 0.5$, where L is the largest and W is the orthogonal diameters of the spheroid. The growth rate of CTOS was calculated by dividing the volume measured on day 6 by that measured on day 1. A CTOS was defined collapsed if it darkened, and its spherical shape was broken with the cells condensed and dispersed.

Statistical analyses

All experiments were conducted in triplicate unless otherwise specified. All mean values $\pm$ SD reported in the Results section were compared by Student's *t* test. Bonferroni correction was applied to correct for multiple testing. Immunostaining of ATP7A in bladder cancers before and after neoadjuvant chemotherapy was compared by using Wilcoxon ranked-sign test.

The combination index was calculated to evaluate the synergism according to the method reported elsewhere.¹³ Briefly, the derived combination index equation for two drugs is $CI = (D_1/(Dx)_1) + (D_2/(Dx)_2)$, where (Dx) 1, (Dx) 2 = the concentration of the tested substance 1 and the tested substance 2 used in the single treatment that was required to decrease the cell number by x%, and (D) 1, (D) 2 = the concentration of the tested substance 1 in combination with the concentration of the tested substance 2 that together decreased the cell number by x%. The CI value quantitatively defines synergism ($CI < 1$), additive effect ($CI = 1$) and antagonism ($CI > 1$). All tests were two-sided, and *P*-values < 0.05 were considered statistically significant.

RESULTS

High-throughput screening identified disulfiram as a synergic agent with CDDP

We used a chemical compound screen approach to explore the potential synergistic interactions of GC with other compounds in human bladder cancer cells. A library of 2098 known compounds was administered alone or combined with IC₂₀ concentrations of GC in UMUC3 and J82 human bladder cancer

Table 2. List of compounds identified in the screening in UMUC3 and J82 human bladder cancer cells

Compound	UMUC3		J82	
	CP alone	GC(IC ₂₀) + CP	CP alone	GC(IC ₂₀) + CP
Bonaphton	0.906	0.074	1.044	0.453
Clioquinol	0.999	0.264	0.85	0.172
Demeclocycline hydrochloride	0.87	0.218	0.962	0.367
Disulfiram	0.99	0.144	1.194	0.464
Fludarabine phosphate	1.005	0.099	0.718	0.088
Furazolidone	1.071	0.393	1.238	0.463
Sulconazole nitrate	1.009	0.323	0.918	0.338
Tyloxapol	0.885	0.203	0.846	0.413

CP compound, GC gemcitabine + cisplatin
Data for CP alone indicate the ratio of OD₄₅₀ for CP alone to OD₄₅₀ for vehicle
Data for GC (IC₂₀) + CP indicate the ratio of OD₄₅₀ for GC + CP to OD₄₅₀ for GC

cells; cell viability was determined after 72 h by using WST-8 assay (Fig. 1a).

We first screened compounds that exhibited sensitisation of GC defined as¹ enhanced inhibitory effect in combination with GC by 50% or more compared with GC alone and² harmless inhibitory effect in sole administration by 30% or less compared with no treatment. The latter criterion was included to exclude those harbouring a strong antitumour effect by themselves since our primary purpose was to identify compounds that sensitise UC cells to chemotherapy. Initial screening identified 21 compounds for UMUC3 (Fig. 1b) and 47 compounds for J82 cells (Fig. 1c). Eight compounds were commonly identified in both (Fig. 1d, Table 2; Supplementary Table 2). Among those eight, disulfiram (DSF), an FDA-approved drug for alcoholism, demonstrated the most reproducible sensitising effect in the secondary screening as shown in Fig. 1e; we selected DSF for further investigation.

Dose-response assays confirmed that DSF enhanced the inhibitory effects of GC in UMUC3 and J82 cells, with similar effects in three other human UC lines (Fig. 1e). To clarify whether DSF sensitises GEM or CDDP, drug interactions were quantified by median-dose-effect analysis. Combination index assay showed synergistic effects of DSF with CDDP but not with GEM in J82, UMUC3 and T24 cells (Fig. 1f).

Co-administration of DSF enhances apoptosis by GC through reactive oxygen species (ROS) accumulation
CDDP cross-links to DNA, while GEM is incorporated into DNA strands, and consequently both induce apoptosis via blockade of DNA replication and transcription.^{14,15} Oxidative damage has also been implicated in the cytotoxic effect of CDDP.¹⁶ To determine the mechanism by which DSF enhances the inhibitory effects of GC, we first examined whether DSF combined with GC enhances apoptosis in UMUC3 and T24 cells. Both early and late apoptotic cell populations were increased by GC in combination with DSF (GC + DSF) compared with GC alone (Fig. 2a). Increased expressions of cleaved PARP and caspase 3 in cells treated with GC + DSF (Fig. 2b) suggested that the apoptosis induced by GC + DSF depended on the caspase pathway.

We next assessed the effect of co-administration of DSF on intracellular redox status by quantitative analysis of intracellular ROS. Both UMUC3 and T24 cells treated with GC + DSF showed significant increases in DCF production after DCFH-DA treatment, suggesting increased ROS production ($p < 0.05$; Fig. 2c, d). The role

of increased ROS production in DSF-induced sensitisation to CDDP was strongly supported by our observations that the antioxidant N-acetyl-L-cysteine (NAC), which effectively blocked DCFH-DA-induced ROS production (Fig. 2c, d), inhibited the induction of apoptosis (Fig. 2a) and cleaved PARP and caspase 3 expressions (Fig. 2b). NAC also partly reversed the inhibition of colony-forming ability in cells treated with GC + DSF (Fig. 2e). These results indicate that co-administration of DSF enhances apoptosis induced by GC, which is partly attributed to ROS accumulation.


Co-administration of DSF alters ATP7A localisation and increases intracellular accumulation of CDDP and Pt-DNA adducts

Cells have been reported to exert resistance to CDDP by accelerating efflux or blocking influx of CDDP.^{17–21} To investigate the effect of DSF on intracellular CDDP accumulation, we quantified intracellular Pt after CDDP treatment in the absence or presence of DSF by using ICP-MS. Intracellular Pt significantly increased in cells treated with GC + DSF compared with GC alone ($p < 0.05$; Fig. 2f). Combination therapy also doubled Pt-DNA adducts (Fig. 2g), a more direct evidence of cross-link between CDDP and DNA that interferes with DNA replication and subsequent mitosis.

Multiple membrane transporters, such as MDR1, MRP1 and ABCG2, have been reported to be associated with drug resistance. Among them, we focused on copper transporters, including CTR1, CTR2, ATP7A and ATP7B, since they are known to incorporate or eliminate Pt.¹⁵ Of these, the expression of ATP7A was decreased by DSF treatment, while the other transporters showed no significant changes (data not shown). The functions of some membrane transporters are regulated by subcellular localisation.^{19,20,22,23} We thus examined the effect of DSF on subcellular localisation of ATP7A, a copper efflux transporter, by using immunofluorescent microscopy (Fig. 2h). ATP7A was recruited to perinuclear *trans*-Golgi upon GC treatment, as reported previously.^{20,23} This perinuclear accumulation is required for ATP7A to function as a Pt efflux transporter. Interestingly, significantly fewer cells showed perinuclear accumulation of ATP7A upon GC + DSF treatment, suggesting that DSF increases intracellular CDDP through inhibiting subcellular localisation and efflux function of ATP7A. These findings suggest that DSF confers sensitivity to CDDP to human UC cells through inhibiting the efflux function of the ATP7A Pt transporter, resulting in increased Pt-DNA adducts, ROS production and cellular apoptosis.

Clinical relevance of ATP7A to sensitivity and resistance to CDDP in human bladder UC

We next examined the clinical relevance of ATP7A in UC patients receiving CDDP-based chemotherapy. We examined ATP7A expression by using IHC on paired bladder UC specimens before and after CDDP-based chemotherapy. We identified 31 patients who received TUR for untreated tumour and neoadjuvant CDDP-based systemic chemotherapy before RC at our hospital to use matched surgical specimens from TUR pre chemotherapy and RC post chemotherapy. All patients had muscle-invasive bladder UC with a single exception of T1 high-grade tumour. Moderate-to-strong ATP7A expression (G2 or G3) was observed in over 70% of pre-treatment tumours (Fig. 2i, left and 2j, left), although we could not evaluate subcellular localisation of ATP7A by using IHC unfortunately. Consistent with previously reported outcomes,²⁴ approximately one-third ($n = 10$) of patients showed marked pathological response, but irrespective of ATP7A expression in pre-treatment tumour tissue (Fig. 2k). ATP7A expression in post-NAC tumours could not be evaluated in the ten patients due to no or little residual tumour lesion. Of the remaining 21 patients with viable residual tumour lesions in RC specimen, 95% (20 of 21) showed moderate-to-strong ATP7A expression (Fig. 2j, right and 2k). Although the results of our in vitro experiments indicated that expression levels of ATP7A do not necessarily reflect its activity,



we found that ATP7A is at least expressed in most muscle-invasive bladder UC, particularly in cases resistant to CDDP-based treatment, suggesting the potential for ATP7A as a target in the treatment of chemoresistance.

DSF-NP enhances CDDP effects in vivo

We next evaluated the efficacy and anticancer effects of CDDP with DSF in vivo. DSF is quickly degraded in the gastrointestinal system, during the hepatic first-pass effect, and in the bloodstream.²⁵ Indeed, in our pilot experiments, oral administration of

the native form of DSF showed little or very modest effects in sensitising mouse tumours to CDDP (data not shown). To deliver DSF to tumours in an unmetabolised form in vivo, micellar DSF-NP was prepared by emulsion-solvent diffusion method (Fig. 3a). DSF-NP was suspended in physiological saline and administered by tail-vein injection. Co-administration of CDDP + DSF-NP to non-tumour-bearing mice showed no adverse effects on body weight (Fig. 3b) and renal function (Fig. 3c).

We investigated the efficacy of DSF-NP + CDDP by using cell-based subcutaneous xenograft models. Tumour-bearing mice

Fig. 2 Co-administration of DSF increases DNA–Pt adducts and ROS production, and enhanced apoptosis with perinuclear localisation of cisplatin efflux transporter ATP7A precluded. **a** Apoptosis was evaluated with Annexin V-FITC/propidium iodide and flow cytometry in cells treated as indicated for 36 h. The effects of the antioxidant (NAC) were also evaluated. **b** Western blot analysis for cleaved PARP and cleaved caspase 3 levels in UMUC3 and T24 cells treated as indicated for 36 h. HeLa cells were treated with 1 μ M of staurosporine (STS), which is known to induce apoptosis. **c, d** ROS production was assessed by DCF. UMUC3 (**c**) and T24 (**d**) cells were treated as indicated for 18 h. The effect of NAC was also evaluated. $*p < 0.05$. **e** Colony-formation assays were performed in UMUC3 and T24 cells treated as indicated with addition of NAC (1 mM) for 72 h. Cells were stained with crystal violet. **f** Whole-cell Pt accumulation. UMUC3 cells were treated with 10 μ M DSF and GC for 1 h, and then whole-cell lysates were subject to ICP-MS assay to quantify intracellular Pt accumulation (normalised by cellular protein amount). $*p < 0.05$. **g** Pt–DNA-adduct accumulation assessed by ICP-MS. UMUC3 cells were treated with 10 μ M DSF and GC for 1 h, and cellular DNA was extracted and subjected to ICP-MS assay (normalised by DNA amount). $*p < 0.05$. **h** Top: confocal microscopy images showing the effect of GC and DSF on the intracellular localisation of ATP7A (green fluorescence). UMUC3 cells were treated as indicated for 1 h. Nuclei were stained with DAPI (blue). Bars indicate 50 μ m. Bottom: quantitative analysis of the percentage of cells with perinuclear accumulation of ATP7A. Seven randomly selected microscopic fields were quantitatively analysed by Image J. $**p < 0.01$. **i** Representative microphotographs of pre-treatment and post-neoadjuvant chemotherapy (post-chemotherapy) bladder urothelial carcinoma by using H&E and ATP7A staining. Bars indicate 100 μ m. **j** Distribution of ATP7A staining intensity score for pre-treatment ($n = 31$) and post-chemotherapy ($n = 21$) tumours. Post-chemotherapy tumours could not be evaluated in ten cases with no or very little viable tumour lesions (pT0 in 4, pTis in 4, pT1 in 1 and pT3b in 1). **k** Statistically significant changes in ATP7A staining intensity score between pre-treatment and post-chemotherapy tumours in the 31 patients (Wilcoxon's ranked-sign test was applied for 21 patients with post-chemotherapy residual tumour)

were treated with DSF-NP and CDDP at doses determined in advance that individually did not significantly inhibit tumour growth. Compared with CDDP alone, the combination treatment significantly inhibited tumour growth by 45% in UMUC3 ($p < 0.01$; Fig. 3d) and by 40% in T24 xenograft models ($p < 0.01$; Fig. 3e). Tumours treated with DSF-NP + CDDP also exhibited increased Pt–DNA adducts (Fig. 3f, top and Fig. 3g) and apoptosis (Fig. 3f, bottom and Fig. 3h), consistent with our *in vitro* results. Collectively, these results suggest that DSF-NP effectively sensitised cell-based xenograft tumours to CDDP *in vivo* via increasing intracellular accumulation of CDDP and consequent apoptosis.

Patient-derived preclinical models for predicting the benefit of DSF co-administration with CDDP

We showed that the majority of muscle-invasive bladder UC harboured resistant cells within the tumour with ATP7A upregulation. In contrast, a subset of patients responded very well to conventional CDDP-based chemotherapy without modification. These findings indicate the need for pre-treatment prediction of clinical efficacy of CDDP-based chemotherapy to identify patients who will benefit from additional DSF. We thus next tried to model a prediction system.

We and others have reported the utility of other patient-derived model systems, namely PDX,^{10,26} organoid culture²⁶ or cancer tissue-originated spheroid (CTOS).^{12,27} To determine whether CTOS, which shows advantages in generating rapid results, can predict treatment efficacy *in vivo*, we first evaluated the efficacy of the combined treatment in PDX and CTOS (Fig. 4a). Bladder cancer (high-grade UC, pT1) tissues obtained by TUR were subcutaneously implanted in the flank of SCID mice and established as a xenograft line that can be stably passaged up to at least ten times.¹⁰ These PDX lines preserved histological characteristics of high-grade UC (Fig. 4a), as reported previously.^{10,26,28} We also established CTOS from the PDX (PDX-derived CTOS), according to the previously reported method.¹² DSF combined with CDDP significantly inhibited PDX tumour growth ($p < 0.05$), while CDDP or DSF-NP alone did not show significant efficacy (Fig. 4b). The combinatorial treatment showed marked efficacy, as demonstrated by shrunk or collapsed spheroids on day 6 (Fig. 4c, d). We observed another example from a different case with high-grade UC, in which we did not observe enhanced inhibitory effect of the combined treatment in PDX or CTOS systems (Supplementary Fig. 1). These results suggest a correlation between CTOS and PDX systems with regard to response to the DSF + CDDP combination treatment.

We next evaluated the patient-derived CTOS culture as drug susceptibility system (Fig. 4e). We successfully obtained sufficient numbers of spheroids for the test in 6 (40%) of 15 patients with

bladder UC (Table 1). Of those six, co-administration of CDDP and DSF showed efficacy in CTOS from four cases (#5, #9, #14 and #15; Fig. 4g, h, j, k, respectively), while one responded to CDDP alone (#12; Fig. 4i) and one did not respond to either treatment (#2; Fig. 4f).

If clinical decisions were made based on the CTOS results, cases #5, #9, #14 and #15 would have been recommended CDDP and DSF combination therapy, while case #12 would have been proposed conventional CDDP-based chemotherapy, and case #2 would have been proposed other chemotherapy or immune checkpoint inhibitors. Unfortunately, only one case (#9) received CDDP-based chemotherapy, making it difficult to confirm the correlation between CTOS assay results and real clinical response. Nonetheless, case #9 showed clinical response to GC chemotherapy, which correlates with the CTOS results. This patient underwent three courses of neoadjuvant GC followed by radical cystectomy for high-grade, pT3N1M0 bladder UC (Supplementary Fig. 2). GC chemotherapy yielded insufficient radiological and pathological response, as would have been predicted from the CTOS assay. Although very preliminary, these findings indicate the potential for the CTOS system as a promising tool for the quick prediction of treatment benefit from DSF combined with CDDP.

DISCUSSION

We identified DSF as a CDDP sensitizer by using high-throughput chemical screening from a library of known compounds. Despite the development of immune checkpoint inhibitors in cancer treatment, these treatments show limitations in practice. Therefore, CDDP-based chemotherapy remains the mainstay treatment for unresectable UC, and how to maximise the benefit from CDDP-based chemotherapy for UC as well as other cancers is a critical question. Our results thus have a strong impact on cancer chemotherapy in general.

Although the initial radiological response rate is relatively high in metastatic UC patients who receive first-line CDDP-based chemotherapy, intrinsic resistance accounts for ~30% of metastatic UC.⁴ In a neoadjuvant setting with standard dose regimens, the pathologic complete response (CR) (pT0) rate is only 10–15%,²⁴ while the CR rate is ~40% in recent studies with dose-dense MVAC protocol.²⁹ Indeed, the CR rate was 13% in our neoadjuvant chemotherapy series, and ten patients had marked pathological regression by the systemic chemotherapy. ATP7A expression in pre-treatment tumour tissue was not associated with excellent pathological response. These tumours might have somatic mutations in *ERCC2*³⁰ or DNA damage response genes, such as *ATM*, *FANCC* and *RB1*,³¹ which sensitise tumour cells to CDDP irrespective of ATP7A activity, although we did not test




Fig. 3 DSF-poly(lactic acid) nanoparticles (DSF-NP) enhance the inhibitory effect of cisplatin treatment in mice. **a** DSF micellar PLA nanoparticles (NP) were prepared via emulsion-solvent diffusion method by using polyvinyl alcohol (PVA). **b, c** Tolerability of the combination regimen. Seven-week-old female athymic mice ($n = 3$) were treated with CDDP (4 mg/kg i.v.) and/or DSF-NP (3 mg/body i.v.). Body weights were measured once a week (**b**), and serum creatinine levels were measured 1 week after administration (**c**). **d, e** Tumour growth rate in the subcutaneous UMUC3 (**d**, $n = 5$ for each group) or T24 xenograft models (**e**, $n = 3$ for each group). Tumour-bearing mice were treated with vehicle, DSF-NP (3 mg/body i.v.) alone, CDDP (4 mg/kg i.v. for UMUC3 and 3 mg/kg i.v. for T24) alone or CDDP in combination with DSF-NP. * $p < 0.05$, ** $p < 0.01$ (CDDP + DSF-NP vs. single treatment). **f** Formation of Pt-DNA adducts (top row, red) and apoptosis (bottom row, green) in tumour cells of UMUC3 xenografts as in **d** detected by anti-Pt-DNA-adduct antibody (day 1) and TUNEL assay (day 15), respectively. Bars indicate 100 μ m. **g, h** Quantitative analysis of Pt-DNA-positive cells (**g**) and TUNEL-positive cells (**h**) in tissue sections from tumours shown in **f**. Three randomly selected microscopic fields were quantitatively analysed with Image J. * $p < 0.05$

them in the present study. However, the remaining patients with resistant tumour lesion showed robust ATP7A expression, suggesting its association with chemoresistance. Therefore, DSF combined with CDDP-based chemotherapy is primarily expected to improve initial response in primary chemotherapy for metastatic UC or preoperative neoadjuvant chemotherapy for localised or locally advanced diseases. This is particularly important as dose-dense MVAC²⁹ or GC³² has shown promising results with a higher rate of radiological or pathological CR than conventional chemotherapy with the standard dose. These findings indicate that improvement in drug delivery is relevant to UC, and we can

expect better response to CDDP-based chemotherapy combined with DSF. This also highlights the importance for efficacy prediction, such as CTOS models. Sensitive tumours to cisplatin may only require standard chemotherapy, whereas other patients would benefit from DSF co-administration with CDDP-based chemotherapy. Our findings demonstrate the potential usefulness of CTOS models as a tool for drug efficacy.

In the present study, we identified DSF by using a drug repurposing strategy. DSF has been used for over six decades as a treatment for alcoholism, with well-established pharmacokinetics, safety and tolerance.³³ Indeed, our preclinical studies showed no




Fig. 4 DSF enhances the inhibitory effect of CDDP in preclinical models. **a** Schematic diagram of PDX and xenograft-derived CTOS model. Subcutaneous PDX lines were established from transurethrally resected specimens of primary tumour (high-grade urothelial carcinoma, pT1; HG, UC and pT1), and PDX tumours were subject to CTOS culture. H&E microphotographs show histological similarity between primary and xenograft tumours. Bars represent 100 μ m. **b** Tumour growth rate in the subcutaneous PDX models. Two weeks after implantation of tumours, mice were randomised into four groups ($n = 3$) and treated with vehicle, DSF-NP (3 mg/body i.v.), CDDP (4 mg/kg i.v.) or CDDP in combination with DSF-NP. * $p < 0.05$ (CDDP + DSF-NP vs. single treatment). **c** Representative images of xenograft-derived CTOS in pre- (day 0) and post-treatment (day 6) settings. Note that CTOS treated with CDDP and DSF collapsed, while others grew and maintained a spheroid shape. **d** Relative volumes of spheroids on day 6 to those on day 0. **e** Schematic diagram of the direct primary tumour-derived CTOS model. Transurethrally resected specimens of primary tumours were directly subject to CTOS culture. **f–k** Representative images of CTOS derived from primary tumours from five patients pre- (day 0) and post treatment (day 6) (left), and relative volumes of spheroids on day 6 to those on day 0 (right)

severe adverse effects in mice, given clinically applied doses of DSF and CDDP. Moreover, we identified very few reports on adverse events for DSF with CDDP and other Pt agents in a public database such as the US Food and Drug Administration Adverse Event Reporting System (FAERS, <https://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/surveillance/adversedrugeffects/ucm070093.htm>) and the Japanese Adverse Drug Event Report (JADER, <https://www.pmda.go.jp/safety/info-services/drugs/adr-info/suspected-adr/0006.html>). Thus, repurposing of DSF to a chemotherapy sensitizer is a promising treatment strategy supported by sufficient regulatory information.

DSF has been a previous candidate for drug repurposing in oncology. Several preclinical studies showed that DSF has anticancer activity.^{34–39} Sodium dithiocarb, a DSF metabolite, was used to treat high-risk human breast cancer in a clinical trial.⁴⁰ DSF also enhanced the anticancer efficacy of chemotherapeutic agents and was effective as a single agent.⁴¹ Other mechanisms for the anticancer activity of DSF have been reported. DSF inhibits proteasome activity.⁴² DSF also chelates bivalent metals and forms complexes with copper, which enhances its antitumour activity.⁴³ A recent epidemiological study supports these findings; patients who continuously used DSF had a lower risk of death from cancer compared with those who stopped using DSF at their diagnosis,³⁹ suggesting that metabolites of DSF also have some antitumour effects. DSF also exhibits tumour-suppressing effects by blocking NPL4. Thus, anticancer effects of DSF have long been known. However, it is noteworthy that the present study is the first report identifying DSF as a CDDP sensitizer via an unbiased, systematic approach of chemical library screening.

Here we demonstrated for the first time that DSF acts as a CDDP sensitizer *in vivo* by using a PDX model. The unmodified form of DSF is extremely unstable.²⁵ Indeed, little sensitizing activity was observed with oral administration of DSF in our model. Nanocarriers have recently attracted attention as antitumour drug delivery systems,^{44,45} and other researchers have also generated DSF nanoparticles.^{11,46,47} Although the preparation methods need improvement, we demonstrated that DSF-NP can enhance intratumoural accumulation of Pt-DNA adducts and apoptosis. We also expect that enhanced permeability and retention (EPR)⁴⁸ can strengthen the cancer-specific efficacy of DSF. Moreover, nano-formulation is also promising in allowing labelling for specific uptake by cancer cells.⁴⁹ On the other hand, DSF-NP has never been used in human, which may weaken the advantage of drug repurposing. Careful safety assessment will be needed before clinical use of DSF-NP.

We also report a previously unknown association between DSF and ATP7A in chemoresistance. We demonstrated that DSF increased intracellular accumulation of Pt-DNA adducts and sensitization to CDDP. ATP7A is an important transporter for copper and Pt, and its congenital dysfunction causes Menkes disease.^{19,22,23,50} Importantly, subcellular localisation of ATP7A is a determinant for its transporter activity,^{23,50} which may be why previous studies by using gene expression analysis failed to identify the involvement of ATP7A in chemoresistance. We found that ATP7A was recruited to Golgi body in response to CDDP in the absence of DSF, and co-administration of DSF prevented this subcellular re-localisation.

Based on the results, it is expected that co-administration of DSF-NP yields an antitumour efficacy of low-dose CDDP equivalent to that obtained at the standard doses. This indicates that DSF-NP may be useful for CDDP-ineligible patients who have impaired renal function, which limits the dose of CDDP. Co-administration of DSF-NP may provide benefit from CDDP at a tolerable dose. On the other hand, one concern is that DSF-NP may increase the risk of CDDP-induced nephrotoxicity, since the cancer-specific mechanism of action of DSF-NP has not been clearly determined. In this regard, however, our *in vivo* pilot study showed that co-administration of DSF-NP did not

induce renal dysfunction as assessed by serum creatinine. Furthermore, our *in vivo* pilot studies showed no sign of significant adverse effects, including gastrointestinal and haematological toxicities.

We also believe that co-administration of DSF-NP with CDDP is worth exploring for patients showing acquired resistance after initial response to CDDP-based chemotherapy. Recent publications have attributed acquired chemoresistance to cellular hierarchy with differential chemosensitivities, which leads to repopulation of tumours with resistant cells.^{51,52} Therefore, improvement in chemosensitivity by DSF-NP seems relevant even to the acquired resistance, although the functional significance of ATP7A with regard to each hierarchical population in UC should be studied in the future.

Recently, the usefulness of 3D cell cultures, such as organoid²⁶ and CTOS,¹² has attracted attention in cancer research. Lee et al.²⁶ showed that organoids of bladder cancer inherited the biological properties of clinical specimens, and can be used for drug screening. We confirmed that drug susceptibility by using our CTOS system was parallel with PDX, indicating that it is a promising tool to predict whether combination treatment will be effective or not. These 3D cell culture systems show important advantages in quick establishment, low cost and technical feasibility for drug susceptibility assessment.

The present study has several limitations. The initial screening strategy was aimed to identify compounds that sensitise GC chemotherapy; however, later analyses showed that DSF sensitises tumour cells to CDDP but not GEM. Therefore, it is not clear whether GEM has any role in this context. We only partially clarified the mechanism of action for DSF sensitising cancer cells to CDDP. Particularly, we did not address the link between Pt-DNA adducts and ROS production, which has not been fully elucidated and seems to be beyond the scope of the present study. *In vivo* models used in the present study were based on subcutaneous tumour, but not orthotopic. Although we demonstrated potential clinical application for efficacy prediction by using a patient-derived CTOS system, the number of cases was limited, and they included non-muscle-invasive diseases. Since the establishment of a sufficient number of CTOS from muscle-invasive bladder cancer is relatively difficult at present, we conducted CTOS assays including non-muscle-invasive bladder cancer in the study. In addition, many of the CTOS assays in the study were done as a single experiment. With future modification of the CTOS system, those experiments can be done in triplicate. Overcoming this will make it possible to conduct sensitivity prediction tests that more closely match the clinical needs. Nonetheless, we present a successful example for a novel strategy to enhance the efficacy of CDDP-based chemotherapy, from high-throughput chemical screening of repositionable drugs, via functional verification and development of drug susceptibility evaluation systems by using *in vitro* and *in vivo* models, to *in silico* screening for safety assessment prior to clinical application.

ACKNOWLEDGEMENTS

The authors thank Gabrielle White Wolf, PhD, from Edanz Group (www.edanzgroup.com/ac) for editing a draft of this paper. The authors thank the members of the laboratory at the Department of Urology, Kyoto University Graduate School of Medicine for their intellectual support, and Ms. Junko Hirao for her excellent technical assistance.

AUTHOR CONTRIBUTIONS

Conception and design: Y.K. and T.K. Development of methodology: Y.K., A.H., R.T., K.T., K.N. and Y.Ta. Acquisition of data: Y.K., A.H. and K.T. Analysis and interpretation of data: Y.K., Y.Te., K.T., K.N., Y.O. and T.K. Writing, review and/or revision of the paper: Y.K., Y.Te., K.N., T.I., Y.Ta., Y.O., O.O. and T.K. Administrative, technical or material support: R.S., K.Mu., K.Ma., S.A. and T.Y. Study supervision: O.O. and T.K.

ADDITIONAL INFORMATION

Supplementary information is available for this paper at <https://doi.org/10.1038/s41416-019-0609-0>.

Competing interests: The authors declare no competing interests.

Ethics approval and consent to participate: The presented research was conducted with the ethical standards that promote and ensure respect and integrity for all human subjects who participated, and justified by the potential benefit to the patient, all in accordance with the Declaration of Helsinki. The collection and use of material for molecular studies was approved by the Institutional Review Board at Kyoto University Graduate School of Medicine (#G0052-17). All patients were informed prior to surgery and gave consent for using their tumour samples during and after the study. All animal experiments were conducted in accordance with the guidelines of the Laboratory Protocol of Animal Care and Use Committee, Kyoto University.

Funding: This study was partly supported by JSPS Grants-in-Aid for Young Scientists (A) from Japanese Society for the Promotion of Science (JSPS) (to T.K. #25713055) and Grant-in-Aid for JSPS Research Fellow (to Y.K. #16J03059).

Consent to publish: All authors have read the paper and given consent for publication.

Data availability: All data and material are available upon request.

Note: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

REFERENCES

1. The Global Cancer Observatory: International Agency for Research on Cancer, World Health Organization; 2018. [Available from: <https://gco.iarc.fr/>].
2. Stenzl, A., Cowan, N. C., De Santis, M., Kuczyk, M. A., Merseburger, A. S., Ribal, M. J. et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. *Eur. Urol.* **59**, 1009–1018 (2011).
3. Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J. L., Fong, L. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. *New Engl. J. Med.* **376**, 1015–1026 (2017).
4. von der Maase, H., Sengelov, L., Roberts, J. T., Ricci, S., Dogliotti, L., Oliver, T. et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. *J. Clin. Oncol.* **23**, 4602–4608 (2005).
5. Corbett, A., Pickett, J., Burns, A., Corcoran, J., Dunnett, S. B., Edison, P. et al. Drug repositioning for Alzheimer's disease. *Nat. Rev. Drug Discov.* **11**, 833–846 (2012).
6. Ma, Y., Yu, W. D., Trump, D. L. & Johnson, C. S. 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models. *Cancer* **116**, 3294–3303 (2010).
7. Kobayashi, T., Inoue, T., Shimizu, Y., Terada, N., Maeno, A., Kajita, Y. et al. Activation of Rac1 is closely related to androgen-independent cell proliferation of prostate cancer cells both in vitro and in vivo. *Mol. Endocrinol.* **24**, 722–734 (2010).
8. Matsui, Y., Ueda, S., Watanabe, J., Kuwabara, I., Ogawa, O. & Nishiyama, H. Sensitization effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species. *Cancer Res.* **67**, 1212–1220 (2007).
9. Terada, N., Shimizu, Y., Kamba, T., Inoue, T., Maeno, A., Kobayashi, T. et al. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model. *Cancer Res.* **70**, 1606–1615 (2010).
10. Inoue, T., Terada, N., Kobayashi, T. & Ogawa, O. Patient-derived xenografts as in vivo models for research in urological malignancies. *Nat. Rev. Urol.* **14**, 267–283 (2017).
11. Song, W., Tang, Z., Shen, N., Yu, H., Jia, Y., Zhang, D. et al. Combining disulfiram and poly(L-glutamic acid)-cisplatin conjugates for combating cisplatin resistance. *J. Controlled Release* **231**, 94–102 (2016).
12. Yoshida, T., Okuyama, H., Endo, H. & Inoue, M. Spheroid cultures of primary urothelial cancer cells: cancer tissue-originated spheroid (CTOS) method. *Methods Mol. Biol.* **1655**, 145–153 (2018).

13. Chou, T. C. & Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. *Adv. Enzym. Regul.* **22**, 27–55 (1984).
14. Chaney, S. G., Campbell, S. L., Temple, B., Bassett, E., Wu, Y. & Faldu, M. Protein interactions with platinum-DNA adducts: from structure to function. *J. Inorg. Biochem.* **98**, 1551–1559 (2004).
15. Kelland, L. The resurgence of platinum-based cancer chemotherapy. *Nat. Rev. Cancer* **7**, 573–584 (2007).
16. Benhar, M., Dalyot, I., Engelberg, D. & Levitzki, A. Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. *Mol. Cell. Biol.* **21**, 6913–6926 (2001).
17. Ishida, S., Lee, J., Thiele, D. J. & Herskowitz, I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. *Proc. Natl Acad. Sci. USA* **99**, 14298–14302 (2002).
18. Katano, K., Kondo, A., Safaei, R., Holzer, A., Samimi, G., Mishima, M. et al. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. *Cancer Res.* **62**, 6559–6565 (2002).
19. Safaei, R., Holzer, A. K., Katano, K., Samimi, G. & Howell, S. B. The role of copper transporters in the development of resistance to Pt drugs. *J. Inorg. Biochem.* **98**, 1607–1613 (2004).
20. Samimi, G., Katano, K., Holzer, A. K., Safaei, R. & Howell, S. B. Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. *Mol. Pharmacol.* **66**, 25–32 (2004).
21. Holzer, A. K., Manorek, G. H. & Howell, S. B. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. *Mol. Pharmacol.* **70**, 1390–1394 (2006).
22. Kalayda, G. V., Wagner, C. H., Buss, I., Reedijk, J. & Jaehde, U. Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells. *BMC Cancer* **8**, 175 (2008).
23. Samimi, G., Safaei, R., Katano, K., Holzer, A. K., Rochdi, M., Tomioka, M. et al. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. *Cancer Res.* **10**, 4661–4669 (2004).
24. Meeks, J. J., Bellmunt, J., Bochner, B. H., Clarke, N. W., Daneshmand, S., Galsky, M. D. et al. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. *Eur. Urol.* **62**, 523–533 (2012).
25. Johansson, B. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. *Acta Psychiatr. Scandinavica Supplementum.* **369**, 15–26 (1992).
26. Lee, S. H., Hu, W., Matulay, J. T., Silva, M. V., Owczarek, T. B., Kim, K. et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. *Cell* **173**, 515–28.e17 (2018).
27. Okuyama, H., Yoshida, T., Endo, H., Nakayama, M., Nonomura, N., Nishimura, K. et al. Involvement of heregulin/HER3 in the primary culture of human urothelial cancer. *J. Urol.* **190**, 302–310 (2013).
28. Abe, T., Tada, M., Shinohara, N., Okada, F., Itoh, T., Hamada, J. et al. Establishment and characterization of human urothelial cancer xenografts in severe combined immunodeficient mice. *Int. J. Urol.* **13**, 47–57 (2006).
29. Zargar, H., Shah, J. B., van Rhijn, B. W., Daneshmand, S., Bivalacqua, T. J., Spiess, P. E. et al. Neoadjuvant dose dense MVAC versus gemcitabine and cisplatin in patients with cT3-4aN0M0 bladder cancer treated with radical cystectomy. *J. Urol.* **199**, 1452–1458 (2018).
30. Van Allen, E. M., Mouw, K. W., Kim, P., Iyer, G., Wagle, N., Al-Ahmadie, H. et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. *Cancer Discov.* **4**, 1140–1153 (2014).
31. Plimack, E. R., Dunbrack, R. L., Brennan, T. A., Andrade, M. D., Zhou, Y., Serebriiskii, I. G. et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. *Eur. Urol.* **68**, 959–967 (2015).
32. Iyer, G., Balar, A. V., Milowsky, M. I., Bochner, B. H., Dalbagni, G., Donat, S. M. et al. Multicenter prospective phase II trial of neoadjuvant dose-dense gemcitabine plus cisplatin in patients with muscle-invasive bladder cancer. *J. Clin. Oncol.* **36**, 1949–1956 (2018).
33. Iljin, K., Ketola, K., Vainio, P., Halonen, P., Kohonen, P., Fey, V. et al. High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. *Clin. Cancer Res.* **15**, 6070–6078 (2009).
34. Irving, C. C., Tice, A. J. & Murphy, W. M. Inhibition of N-n-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary bladder cancer in rats by administration of disulfiram in the diet. *Cancer Res.* **39**, 3040–3043 (1979).
35. Chen, D., Cui, Q. C., Yang, H. & Dou, Q. P. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. *Cancer Res.* **66**, 10425–10433 (2006).

36. Zha, J., Chen, F., Dong, H., Shi, P., Yao, Y., Zhang, Y. et al. Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF- κ B pathway inhibition. *J. Transl. Med.* **12**, 163 (2014).
37. Safi, R., Nelson, E. R., Chitneni, S. K., Franz, K. J., George, D. J., Zalutsky, M. R. et al. Copper signaling axis as a target for prostate cancer therapeutics. *Cancer Res.* **74**, 5819–5831 (2014).
38. Liu, P., Wang, Z., Brown, S., Kannappan, V., Tawari, P. E., Jiang, W. et al. Liposome encapsulated Disulfiram inhibits NF κ B pathway and targets breast cancer stem cells in vitro and in vivo. *Oncotarget* **5**, 7471–7485 (2014).
39. Skrott, Z., Mistrik, M., Andersen, K. K., Friis, S., Majera, D., Gursky, J. et al. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. *Nature* **552**, 194–199 (2017).
40. Dufour, P., Lang, J. M., Giron, C., Duclos, B., Haehnel, P., Jaeck, D. et al. Sodium dithiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study. *Biotherapy (Dordr., Neth.)* **6**, 9–12 (1993).
41. Lun, X., Wells, J. C., Grinshtein, N., King, J. C., Hao, X., Dang, N. H. et al. Disulfiram when combined with copper enhances the therapeutic effects of temozolomide for the treatment of glioblastoma. *Clin. Cancer Res.* **22**, 3860–3875 (2016).
42. Lovborg, H., Oberg, F., Rickardson, L., Gullbo, J., Nygren, P. & Larsson, R. Inhibition of proteasome activity, nuclear factor- κ B translocation and cell survival by the antialcoholism drug disulfiram. *Int. J. Cancer J. Int. du Cancer* **118**, 1577–1580 (2006).
43. Allensworth, J. L., Evans, M. K., Bertucci, F., Aldrich, A. J., Festa, R. A., Finetti, P. et al. Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer. *Mol. Oncol.* **9**, 1155–1168 (2015).
44. Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R. & Langer, R. Nano-carriers as an emerging platform for cancer therapy. *Nat. Nanotechnol.* **2**, 751–760 (2007).
45. Yang, X. Z., Dou, S., Sun, T. M., Mao, C. Q., Wang, H. X. & Wang, J. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy. *J. Controlled Release* **156**, 203–211 (2011).
46. Song, W., Tang, Z., Lei, T., Wen, X., Wang, G., Zhang, D. et al. Stable loading and delivery of disulfiram with mPEG-PLGA/PCL mixed nanoparticles for tumor therapy. *Nanomedicine: NBM* **12**, 377–386 (2015).
47. Wang, Z., Tan, J., McConville, C., Kannappan, V., Tawari, P. E., Brown, J. et al. Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells. *Nanomedicine: NBM* **13**, 641–657 (2016).
48. Zhang, B., Hu, Y. & Pang, Z. Modulating the Tumor Microenvironment to Enhance Tumor Nanomedicine Delivery. *Front. Pharmacol.* **8**, 952 (2017).
49. Fiandra, L., Mazzucchelli, S., De Palma, C., Colombo, M., Allevi, R., Sommaruga, S. et al. Assessing the in vivo targeting efficiency of multifunctional nanoconstructs bearing antibody-derived ligands. *ACS Nano* **7**, 6092–6102 (2013).
50. Veldhuis, N. A., Gaeth, A. P., Pearson, R. B., Gabriel, K. & Camakaris, J. The multi-layered regulation of copper translocating P-type ATPases. *Biometals: an international journal on the role of metal ions in biology. Biochem., Med.* **22**, 177–190 (2009).
51. Kurtova, A. V., Xiao, J., Mo, Q., Pazhanisamy, S., Krasnow, R., Lerner, S. P. et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. *Nature* **517**, 209–213 (2015).
52. Chan, K. S. Molecular pathways: targeting cancer stem cells awakened by chemotherapy to abrogate tumor repopulation. *Clin. Cancer Res.* **22**, 802–806 (2016).